|
KMID : 0363220180560100581
|
|
Korean Journal of Dermatology
2018 Volume.56 No. 10 p.581 ~ p.593
|
|
|
Treatment of Atopic Dermatitis
|
|
Han Tae-Young
Na Chan-Ho
Lee Ji-Hyun
Kim Hye-One
Park Chang-Ook
Seo Young-Joon
Son Sang-Wook
Shin Min-Kyung
Ahn Ji-Young
Lee Yang-Won
Jang Yong-Hyun
Park Young-Lip
Lew Bark-Lynn
|
|
|
Abstract
|
|
|
|
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.
|
|
|
KEYWORD
|
|
|
Atopic dermatitis, Guideline, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|